Epithelialmesenchymal transition (EMT) is an evolutionary conserved developmental process, which is evoked during tumour invasion and metastasis. In the tumour microenvironment, a variety of resident and recruited cells participate in tumour progression. Kawata et al. demonstrated an experimental model where proinflammatory cytokines derived from macrophages could enhance EMT of cancer cells. Endothelialmesenchymal transition (EndMT) is originally observed during heart development, and recent studies suggest its role in pathological settings such as cancer and fibrosis. Mihira et al. demonstrated a line of evidence showing endothelial cell plasticity to undergo EndMT in vitro. Both in EMT and EndMT, transforming growth factor-b played pivotal roles, and multiple downstream mechanisms were used, depending on cell context. These recent works unraveled discrete regulatory networks in mesenchymal transition of epithelial and endothelial cells.
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Cancer is conceivable as a new organ threatening the host's life. Previous studies have focused on genetic or epigenetic alterations intrinsic to cancer cells, while tumour stroma draws increasing attention as a key determinant of tumour progression, which includes tumour vessels, cancer-associated fibroblasts (CAFs) and tumour-associated macrophages (TAMs) (1) . Transforming growth factor (TGF)-b exerts diverse effects on tumourstromal interaction. Smads are pivotal signal transducers of TGF-b, while non-Smad pathways are also activated, such as mitogen-activated protein kinase, phosphoinositide 3-kinase and small GTPases such as RhoA (2) .
Epithelialmesenchymal transition (EMT) is a biological process where polarized epithelial cells undergo phenotypic changes into mesenchymal cells with enhanced invasiveness, survival and extracellular matrix production (Fig. 1) . EMT is originally observed during gastrulation and embryogenesis and is implicated in cancer invasion and metastasis. The hallmarks of EMT are E-cadherin downregulation, subsequent loss of cell adhesions and cytoskeletal alterations. Concomitantly, mesenchymal markers are upregulated, one of which is a-smooth muscle actin (a-SMA), a marker for pericytes or vascular smooth muscle cells (VSMCs), as well as myofibroblasts or CAFs. Thus, EMT consists of multi-step cellular changes, probably regulated in differential and sequential manners (3). Several transcription factors are involved in E-cadherin repression. These include Snail family (Snail and Slug), dEF1 (ZEB1), SIP1 (ZEB2) and bHLH factors (Twist and E12/E47), all of which are regulated by TGF-b. The miR-200 family also regulates EMT by targeting dEF1 and SIP1 (4) . Countering the effect of TGF-b, thyroid transcription factor-1 inhibits EMT in lung cancer cells (5) . TGF-b-mediated Rho signals are also implicated in EMT, particularly through reorganization of cytoskeletons (6) . On the other hand, regulatory mechanisms of mesenchymal markers are poorly defined.
The work by Kawata et al. (7) showed that proinflammatory cytokines derived from macrophages, especially tumour necrosis factor-a, could enhance EMT of cancer cell, cooperatively with TGF-b. Since TGF-b exerts immunosuppressive effects in general, it is intriguing how inflammatory signals are integrated into EMT programs (8) . These results suggest that macrophages play active roles in favour of tumour progression, implying the role of TAMs to promote EMT (Fig. 1) . Moreover, their findings provide a novel insight into the pathophysiology of cancer associated with chronic inflammation, such as liver cirrhosis and lung fibrosis.
During heart development, cardiogenic mesodermal cells give rise to two types of heart cells, myocardial and endocardial cells. Endocardial cells acquire endothelial markers, such as VE-cadherin and CD31. A population of endocardial cells in the atrioventricular canal differentiates into the mesenchymal heart cushion cells, forming cardiac septa and valves. Mechanistic studies have demonstrated roles for TGF-b and Notch pathways (9) . Similar to this process, endothelialmesenchymal transition (EndMT) has been documented in cardiac fibrosis or other fibrotic diseases, as the source of fibroblasts (10) . Furthermore, lineage tracing studies demonstrated that EndMT accounts for a considerable proportion of CAFs (Fig. 1) , whose origins have been previously attributed to local fibroblasts or recruitment of bone marrow-derived precursors (11, 12) . So far, multiple mesenchymal markers have been used to demonstrate EndMT, which include those for fibroblasts and VSMCs, such as FSP1, a-SMA and SM22a. Recently, it has also been shown that endothelial cells differentiate into multipotent stem-like cells, which give rise to chondrocytes and osteoblasts (13) .
Epithelial cells are derived from endoderm, whereas endothelial cells are originally from mesoderm, as most of mesenchymal cells. Endothelial cells and mural cells (pericytes and VSMCs) can originate from common progenitors in the embryonic stem cell (ESC) differentiation model (14) . Hence, EMT and EndMT appear distinct from the viewpoint of development. On the other hand, there seem to be shared mechanisms between EMT and VSMC differentiation. Myocardinrelated transcription factors (MRTFs) participate in VSMC and cardiomyocyte differentiation (15), whereas they induce EMT via interaction with SRF or Smad3 to regulate cytoskeletal genes or Slug transcription (16) . In epithelial cells, dEF1 induced by TGF-b binds to E-cadherin promoter and represses its transcription (17), whereas dEF1 also regulates VSMC differentiation by transactivating a-SMA, through interaction with SRF or Smad3 (18) . Furthermore, E-cadherin repressor, Snail, is required for mesenchymal differentiation in ESC-derived endothelial cells (19) .
As compared to EMT and VSMC differentiation, molecular mechanisms underlying EndMT are largely unknown. Mihira et al. Many questions arise from the above-mentioned studies. Recent studies demonstrate that CAFs promote cancer cell invasion; however, their roles in EMT remain unanswered (21) . The pathological significance of EndMT could be further studied in disease models such as atherosclerosis and tumour angiogenesis. It is plausible that many of EMT regulators play roles in orchestrating EndMT, and inflammatory signals may modulate this process. There may be differential regulations for epithelial, endothelial and mesenchymal markers. In previous studies of EndMT, various mesenchymal markers have been exploited, thus EndMT may yield heterogeneous populations, as observed in CAFs (12) . Recent studies are in favour of the idea that myofibroblasts in fibrotic diseases are derived from pericytes (22) . Cell fate mapping strategy has been used to demonstrate EMT or EndMT in disease models, and studies using multiple markers would further reveal mesenchymal subpopulations with different origins. A. Saito
